Pharmacokinetics of amikacin in critically ill neonatal foals treated for presumed or confirmed sepsis

Abstract

Fourteen foals less than four days of age were treated with the aminoglycoside, amikacin sulphate, and either penicillin or ampicillin for septicaemia, pneumonia, and/or failure of passive immunoglobulin transfer. Serum amikacin concentrations were determined at three times during an 8 or 12 h dosing interval. A 7.0 mg/kg bodyweight dose of amikacin every 8 h was appropriate. Prematurity did not influence mortality. All seven premature foals survived, whereas four of the seven full term foals died. Uraemia in three foals was caused by urinary bladder rupture; amikacin-induced nephrotoxicity was not recognised by clinical chemistries (elevations in serum creatinine or blood urea nitrogen concentrations) or post-mortem findings.